CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Phase 1

Completed

Conditions: Hemophilia B

Interventions: Genetic: AAV5-hFIX

First Posted Date: 2015-03-24

Last Posted Date: 2022-06-27

Lead Sponsor: CSL Behring

Target Recruit Count: 10

Registration Number: NCT02396342

Locations: 🇳🇱
uniQure Investigative Site, Utrecht, Netherlands

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Completed

Conditions: Hemorrhage

Interventions: Biological: Kcentra®
Biological: Plasma

First Posted Date: 2014-12-18

Last Posted Date: 2021-05-26

Lead Sponsor: CSL Behring

Target Recruit Count: 2238

Registration Number: NCT02319460

Locations: 🇺🇸
Study Site, Oakland, California, United States

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Phase 3

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: C1-esterase inhibitor

First Posted Date: 2014-12-12

Last Posted Date: 2018-11-14

Lead Sponsor: CSL Behring

Target Recruit Count: 126

Registration Number: NCT02316353

Locations: 🇬🇧
Study Site, London, United Kingdom

Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects

Phase 3

Completed

Conditions: Acute Major Bleeding
Reversal of Coagulopathy

Interventions: Biological: BE1116 (Prothrombin Complex Concentrate)

First Posted Date: 2014-11-02

Last Posted Date: 2016-05-04

Lead Sponsor: CSL Behring

Target Recruit Count: 11

Registration Number: NCT02281201

Locations: 🇯🇵
Nippon Medical School Hospital, Sendagi, Bunkyo, Japan
🇯🇵
Tohoku University Hospital, Aoba-ku, Sendai, Japan
🇯🇵
Kurashiki Central Hospital, Miwa, Kurashiki, Japan

and more 8 locations

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Phase 3

Completed

Conditions: Severe Hemophilia A
Hemophilia A

Interventions: Biological: rVIII-SingleChain

First Posted Date: 2014-06-24

Last Posted Date: 2021-10-27

Lead Sponsor: CSL Behring

Target Recruit Count: 246

Registration Number: NCT02172950

Locations: 🇪🇸
Study Site 7240023, Valencia, Spain
🇹🇭
Study Site 7640003, Songkhla, Thailand
🇺🇦
Study Site 8040005, Lviv, Ukraine

and more 61 locations

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Phase 2

Completed

Conditions: Acute Myocardial Infarction

Interventions: Biological: CSL112
Biological: Placebo

First Posted Date: 2014-04-09

Last Posted Date: 2021-03-15

Lead Sponsor: CSL Behring

Target Recruit Count: 1267

Registration Number: NCT02108262

Locations: 🇧🇬
Study Site 12021, Haskovo, Bulgaria
🇧🇬
Study Site 12013, Sofia, Bulgaria
🇨🇦
Study Site - 13007, Quebec, Canada

and more 186 locations

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Phase 3

Completed

Conditions: Congenital Hemophilia A

Interventions: Biological: rVIII-SingleChain

First Posted Date: 2014-03-21

Last Posted Date: 2017-01-27

Lead Sponsor: CSL Behring

Target Recruit Count: 84

Registration Number: NCT02093897

Locations: 🇺🇦
Study Site, Lviv, Ukraine

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Phase 3

Completed

Conditions: Hemophilia B

Interventions: Biological: rIX-FP

First Posted Date: 2014-02-04

Last Posted Date: 2022-07-14

Lead Sponsor: CSL Behring

Target Recruit Count: 97

Registration Number: NCT02053792

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇦🇺
Royal Children's Hospital, Parkville, Victoria, Australia
🇯🇵
The Hospital of Hyogo College of Medicine, Nishinomiya, Japan

and more 39 locations

Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 3

Completed

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Interventions: Biological: IgPro20

First Posted Date: 2014-01-06

Last Posted Date: 2018-10-02

Lead Sponsor: CSL Behring

Target Recruit Count: 82

Registration Number: NCT02027701

Locations: 🇺🇸
Site Reference 8400166, Kansas City, Kansas, United States
🇺🇸
Site Reference 8400182, Charlotte, North Carolina, United States
🇺🇸
Site Reference 8400181, Birmingham, Alabama, United States

and more 30 locations

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Clazakizumab
Drug: Placebo (Matching with Clazakizumab)

First Posted Date: 2013-12-19

Last Posted Date: 2021-05-12

Lead Sponsor: CSL Behring

Target Recruit Count: 143

Registration Number: NCT02015520

Locations: 🇺🇸
Cincinnati Rheumatic Disease Study Group, Cincinnati, Ohio, United States
🇺🇸
Seattle Rheumatology Associates, Seattle, Washington, United States
🇺🇸
Center For Inflammatory Disease, Nashville, Tennessee, United States

and more 22 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy